Period
recent search
Showing: 1 – 05 of 158 Regulated Information
21 January 2026
21 January 2026
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration…
07 January 2026
07 January 2026
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
06 January 2026
06 January 2026
Ipsen – Half year statement – 2025 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
19 December 2025
19 December 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva…
15 December 2025
15 December 2025
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.